Rhythm Pharmaceuticals (RYTM) Short-term Investments (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Short-term Investments data on file, last reported at $278.5 million in Q1 2026.

• On a quarterly basis, Short-term Investments rose 33.64% year-over-year to $278.5 million in Q1 2026; TTM through Mar 2026 was $278.5 million, a 33.64% increase from a year earlier, with the FY2025 full-year figure at $334.6 million, up 44.6% from the prior year.
• Short-term Investments for Q1 2026 stood at $278.5 million, down from $334.6 million in the prior quarter.
• Over the last five years, Short-term Investments for RYTM reached as high as $364.0 million in Q3 2025 and fell as low as $122.4 million in Q2 2022.
• Historically, Short-term Investments has averaged $209.1 million across 5 years, with a median of $205.6 million in 2022.
• Across the five-year window, Short-term Investments sank 59.04% in 2022 and surged 45.09% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $205.6 million in 2022, then advanced by 4.94% to $215.8 million in 2023, then rose by 7.26% to $231.4 million in 2024, then surged by 44.6% to $334.6 million in 2025, then declined by 16.78% to $278.5 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $278.5 million in Q1 2026, $334.6 million in Q4 2025, and $364.0 million in Q3 2025.